A phase I/II study of lenvatinib (LEN) plus everolimus (EVE) in recurrent and refractory pediatric solid tumors, including CNS tumors

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2020
This article has no abstract
Epistemonikos ID: cad7dba0916ba0b135339f8e07a1ae035e478035
First added on: Feb 13, 2025